Oncosem to Go Public

Oncosem to Go Public Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.Ş. is going public. With 26 years of experience in the sector, the company specializes in the manufacture of equipment, semi-finished components and medical devices used in cancer diagnosis and treatment, as well as the production of diagnostic products and protective equipment.

Exporting to More Than 30 Countries

Currently, one out of every two chemotherapy patients in Turkey receives their chemotherapy drugs prepared in systems manufactured by Oncosem. The company most recently produced antibody and antigen rapid test kits entirely with domestic resources at the beginning of the COVID-19 pandemic and succeeded in exporting these products to more than 20 countries. The company's products, including oncology offerings manufactured with high technology, are today exported to more than 30 countries.

IPO Proceeds to Fund New Investments

The application submitted to the Capital Markets Board for Oncosem's public offering was approved in the bulletin dated 15 December 2022. In the public offering conducted by Info Yatırım, the company's paid-in capital is being increased from TRY 19,900 thousand to TRY 23,850 thousand. 13% of the proceeds targeted from the public offering will be used to finance investments in Germany, the United Kingdom and other foreign markets, such as high-technology equipment, technology transfer, clean rooms and waste systems.

36% to Build New Manufacturing Facility

36% of the IPO proceeds will be allocated to investments in a new manufacturing facility planned to be established. 28% of the said proceeds is planned within the scope of machinery and equipment investments aimed at increasing production capacity, while the remaining 23% of the offering proceeds will be set aside for financing working capital requirements. Through the systems it has established in oncology centers of 50 private and public healthcare institutions across 30 countries and Turkey, Oncosem, which provides support to one out of every two patients by serving both healthcare workers and patients, will take the success story it has written in Turkey to the global arena with the public offering.

Shares Being Offered to Public at TRY 17.50

In the public offering to be conducted using the 'equal distribution' method, 2 million nominal shares belonging to Oncosem Board Chairman Erol Çelik will also be offered for sale. In the public offering, where the demand collection date is 28-29 December 2022, the share price was set at TRY 17.50.

90% of Shares Owned by Erol Çelik

Among the shareholders of Oncosem, whose Board of Directors is chaired by Erol Çelik, who is also the company's founder, are EC Yatırımlar Holding and Bulls Girişim Sermayesi Yatırım Ortaklığı operating under the Lydia Yatırım Holding umbrella. Oncosem, 90% of which is owned by Erol Çelik, holds a 5% stake in EC Yatırımlar Holding; the remaining 5% stake is owned by Bulls Girişim Sermayesi Yatırım Ortaklığı. Lydia Yatırım Holding operates in many different sectors, including real estate, media, micro-mobility, healthcare and renewable energy, with the mission of adding value to the country's economy. The holding invests in entrepreneurial companies in this field. Bulls Girişim Sermayesi Yatırım Ortaklığı, which places the concept of 'sustainability' at the center of its investment policy, has investments in technology, micro-mobility, sports, sustainable innovative energy, healthcare and health technologies.